{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:17:28Z","timestamp":1791980248286,"version":"4.4.0"},"reference-count":36,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Innovate UK grant","award":["104915 (reference 19\/WM\/0111)"],"award-info":[{"award-number":["104915 (reference 19\/WM\/0111)"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autoimmune hepatitis (AIH) is a rare chronic progressive liver disease, managed with corticosteroids and immunosuppressants and monitored using a combination of liver biochemistry and histology. Liver biopsy (gold standard) is invasive, costly and has risk of complications. Non-invasive imaging using multiparametric magnetic resonance (mpMR) can detect the presence and extent of hepatic fibroinflammation in a risk-free manner.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To conduct early economic modelling to assess the affordability of using mpMR as an alternative to liver biopsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medical test costs associated with following 100 patients over a 5-year time horizon were assessed from a National Health Service payor perspective using tariff costs and average biopsy-related adverse events costs. Sensitivity analyses modelling the cost consequences of increasing the frequency of mpMR monitoring within the fixed cost of liver biopsy were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Per 100 moderate\/severe AIH patients receiving an annual mpMR scan (in place of biopsy), early economic modelling showed minimum cost savings of \u00a3232\u2009333. Per 100 mild\/moderate AIH patients receiving three mpMR scans over 5 years estimated minimum cost savings were \u00a3139\u2009400. One-way sensitivity analyses showed increasing the frequency of mpMR scans from 5 to 10 over 5 years in moderate\/severe AIH patients results in a cost saving of \u00a3121\u2009926.20. In patients with mild\/moderate AIH, an increase from 3 to 6 mpMR scans over 5 years could save \u00a373\u2009155.72. In a minimalistic approach, the use of 5 mpMR scans was still cost saving (\u00a35770.48) if they were to replace two biopsies over the 5-year period for all patients with moderate\/severe or mild\/moderate AIH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Integration of mpMR scans in AIH patient pathways leads to significant cost savings when liver biopsy frequency is either reduced or eliminated, in addition to improved patient experience and clinician acceptability as well as providing detailed phenotyping to improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03979053\">NCT03979053<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-058999","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T11:37:04Z","timestamp":1662637024000},"page":"e058999","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["LiverMultiScan as an alternative to liver biopsy to monitor autoimmune hepatitis in the National Health Service in England: an economic evaluation"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03979053","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5615-8657","authenticated-orcid":false,"given":"Mamta","family":"Bajre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Moawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Shumbayawonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane Elizabeth","family":"Carolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Culver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heneghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"2022090808351194000_12.9.e058999.1","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.cgh.2021.01.029","article-title":"The epidemiology of UK autoimmune liver disease varies with geographic latitude","volume":"19","author":"Webb","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022090808351194000_12.9.e058999.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.06.030"},{"key":"2022090808351194000_12.9.e058999.3","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.3748\/wjg.v23.i33.6030","article-title":"Autoimmune hepatitis: standard treatment and systematic review of alternative treatments","volume":"23","author":"Terziroli Beretta-Piccoli","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2022090808351194000_12.9.e058999.4","doi-asserted-by":"crossref","DOI":"10.1007\/s10620-021-07089-w","article-title":"Incidence of complications from percutaneous biopsy in chronic liver disease: a systematic review and meta-analysis","volume":"67","author":"Thomaides-Brears","year":"2022","journal-title":"Dig Dis Sci"},{"key":"2022090808351194000_12.9.e058999.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01691.x"},{"key":"2022090808351194000_12.9.e058999.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.05.001"},{"key":"2022090808351194000_12.9.e058999.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.10.014"},{"key":"2022090808351194000_12.9.e058999.8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.5114\/ceh.2019.87639","article-title":"Transient elastography reliably estimates liver fibrosis in autoimmune hepatitis","volume":"5","author":"Mahmud","year":"2019","journal-title":"Clin Exp Hepatol"},{"key":"2022090808351194000_12.9.e058999.9","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/ajg.2015.139","article-title":"Long-Term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis","volume":"110","author":"Dhaliwal","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2022090808351194000_12.9.e058999.10","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/liv.13724","article-title":"Diagnosis, presentation and initial severity of autoimmune hepatitis (AIH) in patients attending 28 hospitals in the UK","volume":"38","author":"Gordon","year":"2018","journal-title":"Liver Int"},{"key":"2022090808351194000_12.9.e058999.11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94754-9","article-title":"Quantitative multiparametric MRI as a non-invasive stratification tool in children and adolescents with autoimmune liver disease","volume":"11","author":"Janowski","year":"2021","journal-title":"Sci Rep"},{"key":"2022090808351194000_12.9.e058999.12","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/hep4.1687","article-title":"Multiparametric magnetic resonance imaging, autoimmune hepatitis, and prediction of disease activity","volume":"5","author":"Arndtz","year":"2021","journal-title":"Hepatol Commun"},{"key":"2022090808351194000_12.9.e058999.13","article-title":"Correction: characterisation of liver fat in the UK Biobank cohort","volume":"12","author":"Wilman","year":"2017","journal-title":"PLoS One"},{"key":"2022090808351194000_12.9.e058999.14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209340"},{"key":"2022090808351194000_12.9.e058999.15","doi-asserted-by":"crossref","DOI":"10.1002\/nbm.4030","article-title":"Mapping tissue water T\n                  \n                     1\n                  \n                in the liver using the MOLLI T\n                  \n                     1\n                  \n                method in the presence of fat, iron and B\n                  0\n                inhomogeneity","volume":"32","author":"Mozes","year":"2019","journal-title":"NMR Biomed"},{"key":"2022090808351194000_12.9.e058999.16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/apt.14469","article-title":"Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease","volume":"47","author":"Eddowes","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2022090808351194000_12.9.e058999.17","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13284"},{"key":"2022090808351194000_12.9.e058999.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-27560-5","article-title":"Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study","volume":"8","author":"McDonald","year":"2018","journal-title":"Sci Rep"},{"key":"2022090808351194000_12.9.e058999.19","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.115.306561"},{"key":"2022090808351194000_12.9.e058999.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.10.009"},{"key":"2022090808351194000_12.9.e058999.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214921","article-title":"Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver","volume":"14","author":"Bachtiar","year":"2019","journal-title":"PLoS One"},{"key":"2022090808351194000_12.9.e058999.22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203054","article-title":"Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial","volume":"13","author":"Harrison","year":"2018","journal-title":"PLoS One"},{"key":"2022090808351194000_12.9.e058999.23","doi-asserted-by":"crossref","first-page":"101325","DOI":"10.1016\/j.eclinm.2022.101325","article-title":"Quantitative magnetic resonance imaging to aid clinical decision making in autoimmune hepatitis","volume":"46","author":"Heneghan","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2022090808351194000_12.9.e058999.24","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1177\/0272989X19866415","article-title":"Early economic evaluation of diagnostic technologies: experiences of the NIHR diagnostic evidence Co-operatives","volume":"39","author":"Abel","year":"2019","journal-title":"Med Decis Making"},{"key":"2022090808351194000_12.9.e058999.25","unstructured":"Ni M , Borsci S , Bajre M . The Lean Assessment Process (LAP) \u2013 experiences of NIHR London IVD Cooperative working with early stage medical technologies. Prague, Czech Republic, World Congress on Medical Physics & Biomedical Engineering, IUPEM 2017."},{"key":"2022090808351194000_12.9.e058999.26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23584"},{"key":"2022090808351194000_12.9.e058999.27","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.235259"},{"key":"2022090808351194000_12.9.e058999.28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/390916","article-title":"Autoimmune hepatitis: a review of current diagnosis and treatment","volume":"2011","author":"Makol","year":"2011","journal-title":"Hepat Res Treat"},{"key":"2022090808351194000_12.9.e058999.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.03.025"},{"key":"2022090808351194000_12.9.e058999.30","unstructured":"Al-Ghamdi A . Complications of Liver Biopsy. In: Takahashi H , ed. Liver biopsy. Rijeka, Croatia: InTech, 2011: 363\u201370."},{"key":"2022090808351194000_12.9.e058999.31","unstructured":"National Health Service (NHS), 2019\/2020. 2019\/20 National Tariff Payment System: national prices and prices for emergency care services. [Online]. Available: https:\/\/www.england.nhs.uk\/publication\/past-national-tariffs-documents-and-policies\/"},{"key":"2022090808351194000_12.9.e058999.32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e686"},{"key":"2022090808351194000_12.9.e058999.33","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/apt.14968","article-title":"Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom","volume":"48","author":"Dyson","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2022090808351194000_12.9.e058999.34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"2022090808351194000_12.9.e058999.35","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"2022090808351194000_12.9.e058999.36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3748\/wjg.v5.i4.301","article-title":"Liver biopsy:complications and risk factors","volume":"5","author":"Thampanitchawong","year":"1999","journal-title":"World J Gastroenterol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-058999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T11:37:42Z","timestamp":1662637062000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-058999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,8]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/bmjopen-2021-058999"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-058999","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}